Newer therapies for the treatment of metastatic breast cancer: A clinical update

Indian Journal of Pharmaceutical Sciences

Volumn 75, Issue 3, 2013, Pages 251-261

  Mohan, Anjana ^a   Ponnusankar, S ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Breast cancer; clinical benefit rate; combination regimen; metastasis; novel monotherapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABAZITAXEL; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERIBULIN; EVEROLIMUS; EXEMESTANE; FULVESTRANT; HALICHONDRIN B; INIPARIB; IXABEPILONE; LAPATINIB; MOTESANIB; NAVELBINE; OLAPARIB; PACLITAXEL; PEMETREXED; PERTUZUMAB; PLACEBO; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UFT; UNINDEXED DRUG;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; KIDNEY METASTASIS; LIFE EXPECTANCY; LIVER FUNCTION; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84883676063     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.117396     Document Type: Review

References (59)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. Sant M, Capocaccia R, Colerman MP, Berrino F, Gatta G, Micheli A et al.; EUROCARE Working Group. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001;37:1659-67. (Pubitemid 32778613)
3. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BF. Cancer survival among US whites and minorities: A SEER (Surveillance, Epidemiology, and End Results) Program population - based study. Arch Intern Med 2002;162:1985-93.
4. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95. (Pubitemid 41079102)
5. Cortes J, Shaughnessy JO, Blum JL, Vahdat LT, Petrakova K, Chollet P, et al. Eribulin monotherapy versus treatment of physician choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open label randomized study. Lancet 2011;377:914-23.
6. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, et al. Phase 2 study of the Halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracyclines, a taxanes, and capecitabine. J Clin Oncol 2010;28:3922-8.
7. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
8. Howell A. Fulvestrant (Faslodex): Current and future role in breast cancer management. Crit Rev Oncol Hematol 2006;57:265-73. (Pubitemid 43238329)
9. Leo AD, Jerusalem G, Petruzelka L, Torrges R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase 3 trial comparing fulvestrant 250 mg with fulvestrant 500 mg in post menopausal women with estrogen receptor positive advanced breast cancer. J Clin Oncol 2010;28:4594-600.
10. Hudis CA. Trastuzumab mechanism of action and use in clinical practice. N Eng J Med 2007;357:39-51. (Pubitemid 47026733)
11. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich BO, Yang X. The therapeutic effect of anti HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
12. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch C, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow up of a randomized controlled trial. Lancet Oncol 2011;12:236-44.
13. Gianni L, EiermannW, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab verses neoadjuvant chemotherapy alone, in patients with HER2 positive locally advanced breast cancer (the NOAH trial): A randomized controlled superiority trial with a parallel HER2 negative cohort. Lancet 2010;375:377-84.
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic stratergy. Nature 2005;434:917-21. (Pubitemid 40559006)
15. Tutt A, Robson M, Garber JE, Dornchek SM, Audeh MW, Weitzel JN, et al. Oralpoly (ADP ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof of concept trial. Lancet 2010;376:235-44.
16. Franklin MC, Carey KD, Vajdos FF, Leahy DF, Devos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2pertuzumab complex. Cancer Cell 2004;5:317-28. (Pubitemid 38482068)
17. Arteaga CL, Baselga J. Tyrosine kinase inhibitor: Why does the current process of clinical development not apply to them? Cancer Cell 2004;5:525-31. (Pubitemid 38748914)
18. Gianni L, Llado A, Bianchi G, Cortes J, Lehtinen PL, Cameron DA, et al. Open label, phase 2, multicenter, randomised study of efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131-7.
19. Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors 2009;35:332-7.
20. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
21. Smith IE, Pierga JY, Biganzoli L, Funes HC, Thomssen C, Pivot X, et al. First line bevacizumab plus taxanes based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open label study in 2251 patients. Ann Oncol 2011;22:595-602.
22. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczat P, et al. Phase 3 study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
23. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase 2 randomized study of neoadjuvant Everolimus plus letrozole in patients with estrogen receptor positive breast cancer. J Clin Oncol 2009;27:2630-7.
24. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. (Pubitemid 46021510)
25. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
26. Minkwitz GV, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating bevacizumab, everolimus and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the Gepar Quinto trial. Ann Oncol 2011;22:301-6.
27. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracyclines resistance breast cancer. Br J Cancer 2000;82:529-34. (Pubitemid 30085185)
28. Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, et al. A multicenterd dose escalating study of cabazitaxel in combination with capecitabine in patients with metastatic breast cancer progressing after anthracyclines and taxanes treatment: A phase 1/2 study. Eur J Cancer 2011;47:1037-45.
29. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil DM, Kerbreat P, et al. Phase 2 trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52. (Pubitemid 23199126)
30. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first line treatment for patients with metastatic breast cancer. Oncologist 2006;11:42-51.
31. Bedard PL, Chantal BM, Raimondi C, Cardoso F. The role of capecitabine in the management of breast cancer in elderly patients. J Geriatr Oncol 2011;2:72-81.
32. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7. (Pubitemid 350232252)
33. Mao W, Guan X, Tucker S, Li F, He Z, Wang J, et al. Second line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes. Chemotherapy 2011;57:71-6.
34. Fan Y, Xu B, Yuan P, Wang J, Ma F, Li Q, et al. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Chemotherapy 2010;56:340-7.
35. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550. A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37. (Pubitemid 32708699)
36. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase 3 trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracyclines and taxanes. J Clin Oncol 2010;28:3256-63.
37. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M. Anastosole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
38. Pairdaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al. Mature results of randomized phase 2 multicentre study of exemestane versus tamoxifen as first line hormonal therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-8. (Pubitemid 37185285)
39. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenbrg A, Vannetzel JM, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomized phase 3 trial. Lancet 2011;377:321-31.
40. Allie E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple negative breast cancer confers sensitivity to inhibition of poly (ADP-ribose) polymerase. Cancer Res 2009;69:3589-96.
41. Shaughnessy JO, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple negative breast cancer. N Engl J Med 2011;364:205-14.
42. Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12. (Pubitemid 47050840)
43. Boussen H, Cristofanilli M, Zaks DeSilvio M, Salazar V, Spetor N. Phase 2 study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 2010;28:3248-55.
44. Karaman MW, Hergard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
45. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L et al. Motesanib, or open - label bevacizumab, in combination with paclitaxel, as first line treatment for HER2 negative locally recurrent or metastatic breast cancer: A phase 2, randomized, double-blind, placebo-controlled study. Lancet Oncol 2011;12:369-76.
46. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase 2 study of sunitinib malate an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with anthracycline and a taxane. J Clin Oncol 2008;26:1810-6.
47. Mayer El, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, et al. SABRE-B: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first line treatment of metastatic breast cancer. Ann Oncol 2010;21:2370-6.
48. Ogawa Y, Ishikawa T, Chung SH, Lkeda K, Takashima T, Onoda N, et al. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 2003;23:3453-7. (Pubitemid 36975448)
49. Villanueva C, Chaigneau L, Dufresne A, Vuillemin T, Stein U, Demarchi M, et al. Phase 2 trial of paclitaxel and uracil-tegafur in metastatic breast cancer. TEGATAX trial. Breast 2011;30:1-5.
50. Rivera E. Liposomal anthracyclines in metastatic breast cancer: Clinical update. Oncologist 2003;8:3-9. (Pubitemid 37152051)
51. Kerbel RS, Kamen BA. Antiangiogenic basis of low dose metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36. (Pubitemid 38745528)
52. Dellapasqua S, Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, et al. Pegylated liposomal doxorubicin in combination with low dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 2011;30:1-5.
53. Maletmartino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 2002;7:288-323. (Pubitemid 34919955)
54. Liombart CA, Martin M, Harbeck N, Anghel RM, Eniu AE, Verrill MW, et al. A randomized double blind, phase 2 study of two doses of pemetrexed as first line chemotherapy for advanced breast cancer. Clin Cancer Res 2001;13:3652-9.
55. Schneeweiss A, Marme F, Ruiz A, Manikhas AG, Bottini A, Wolf M, et al. A randomized phase 2 trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Ann Oncol 2011;22:609-17.
56. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase 3 randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first line therapy of metastatic or locally advanced human epidermal growth factor receptor 2 positive breast cancer: The HERNATA study. J Clin Oncol 2011;29:264-71.
57. Carter P, Prestal L, Gorman CM, Ridgway JB, Henner D, Wong WL. Humanization of an anti-p 185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
58. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, et al. Multicentre phase three randomized trial comparing docetaxel and trastuzumab as first line chemotherapy for patients with HER2 gene amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 2010;29:149-56.
59. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, et al. Phase 3 multicentre trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high risk breast cancer. J Clin Oncol 2010;28:2958-65.